Evaluation of Serum sCD30 in Renal Transplantation Patients With and Without Acute Rejection

C. Cervelli, G. Fontecchio, M. Scimitarra, R. Azzarone, A. Famulari, F. Pisani, C. Battistoni, B. Di Iulio, D. Fracassi, M. A. Scarnecchia, F. Papola

Research output: Contribution to journalArticlepeer-review


Despite new immunosuppressive approaches, acute rejection episodes (ARE) are still a major cause of early kidney dysfunction with a negative impact on long-term allograft survival. Noninvasive markers able to identify renal ARE earlier than creatinine measurement include sCD30. We sought to establish whether circulating levels of sCD30 in pretransplantation and posttransplantation periods were of clinical relevance to avoid graft damage. Quantitative detection of serum sCD30 was performed using an enzyme-linked immunosorbent assay. Our results demonstrated that the mean concentrations of sCD30 were significantly higher in the sera of renal transplant recipients with ARE (30.04 U/mL) and in uremic patients on the waiting list (37.7 U/mL) compared with healthy controls (HC; 9.44 U/mL), but not nonrejecting patients (12.01 U/mL). Statistical analysis revealed a strong association between high sCD30 levels in posttransplantation sera and ARE risk. This study suggested that sCD30 levels were a reliable predictor of ARE among deceased-donor kidney recipients.

Original languageEnglish
Pages (from-to)1159-1161
Number of pages3
JournalTransplantation Proceedings
Issue number4
Publication statusPublished - May 2009

ASJC Scopus subject areas

  • Surgery
  • Transplantation


Dive into the research topics of 'Evaluation of Serum sCD30 in Renal Transplantation Patients With and Without Acute Rejection'. Together they form a unique fingerprint.

Cite this